Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen

Research output: Contribution to journalReview article

X. Qian, Fransisca Leonard, Y. Wenhao, H. Sudhoff, T. K. Hoffmann, S. Ferrone, A. M. Kaufmann, A. E. Albers

Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.

Translated title of the contributionImmunotherapeutics for head and neck squamous cell carcinoma stem cells
Original languageGerman
Pages (from-to)94-99
Number of pages6
JournalHNO
Volume68
Issue number2
DOIs
StatePublished - Feb 1 2020

PMID: 31996933

Altmetrics

Cite this

Standard

Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen. / Qian, X.; Leonard, Fransisca; Wenhao, Y.; Sudhoff, H.; Hoffmann, T. K.; Ferrone, S.; Kaufmann, A. M.; Albers, A. E.

In: HNO, Vol. 68, No. 2, 01.02.2020, p. 94-99.

Research output: Contribution to journalReview article

Harvard

Qian, X, Leonard, F, Wenhao, Y, Sudhoff, H, Hoffmann, TK, Ferrone, S, Kaufmann, AM & Albers, AE 2020, 'Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen' HNO, vol. 68, no. 2, pp. 94-99. https://doi.org/10.1007/s00106-020-00819-y

APA

Qian, X., Leonard, F., Wenhao, Y., Sudhoff, H., Hoffmann, T. K., Ferrone, S., ... Albers, A. E. (2020). Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen. HNO, 68(2), 94-99. https://doi.org/10.1007/s00106-020-00819-y

Vancouver

Qian X, Leonard F, Wenhao Y, Sudhoff H, Hoffmann TK, Ferrone S et al. Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen. HNO. 2020 Feb 1;68(2):94-99. https://doi.org/10.1007/s00106-020-00819-y

Author

Qian, X. ; Leonard, Fransisca ; Wenhao, Y. ; Sudhoff, H. ; Hoffmann, T. K. ; Ferrone, S. ; Kaufmann, A. M. ; Albers, A. E. / Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen. In: HNO. 2020 ; Vol. 68, No. 2. pp. 94-99.

BibTeX

@article{b4864d3eb11f434eb69b916aa99ccbd9,
title = "Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen",
abstract = "Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.",
keywords = "Cancer nanomedicine, Cancer stem cell, Cancer vaccine, Immunotherapy, Nanotechnology",
author = "X. Qian and Fransisca Leonard and Y. Wenhao and H. Sudhoff and Hoffmann, {T. K.} and S. Ferrone and Kaufmann, {A. M.} and Albers, {A. E.}",
year = "2020",
month = "2",
day = "1",
doi = "10.1007/s00106-020-00819-y",
language = "German",
volume = "68",
pages = "94--99",
journal = "HNO",
issn = "0017-6192",
number = "2",

}

RIS

TY - JOUR

T1 - Immuntherapeutika gegen Kopf-Hals-Plattenepithelkarzinom-Stammzellen

AU - Qian, X.

AU - Leonard, Fransisca

AU - Wenhao, Y.

AU - Sudhoff, H.

AU - Hoffmann, T. K.

AU - Ferrone, S.

AU - Kaufmann, A. M.

AU - Albers, A. E.

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.

AB - Cancer stem cell (CSC)-related therapy resistance has become a new obstacle to the successful application of cancer treatment and head and neck squamous cell carcinoma (HNSCC) is no exception to this finding. Head and neck squamous cell carcinoma is highly immune-suppressive, and recently the immune suppression and invasion of HNSCC-CSCs have been characterized. These characteristics have received research and clinical attention because they would enable the stratification of patients into specific cancer subtypes and, consequently, the establishment of new therapeutic approaches with improved efficacy. This review discusses the feasibility of CSC-targeted strategies and their incorporation with nanotechnology to improve the efficacy of cancer immunotherapy.

KW - Cancer nanomedicine

KW - Cancer stem cell

KW - Cancer vaccine

KW - Immunotherapy

KW - Nanotechnology

UR - http://www.scopus.com/inward/record.url?scp=85078672368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078672368&partnerID=8YFLogxK

U2 - 10.1007/s00106-020-00819-y

DO - 10.1007/s00106-020-00819-y

M3 - Review article

VL - 68

SP - 94

EP - 99

JO - HNO

T2 - HNO

JF - HNO

SN - 0017-6192

IS - 2

ER -

ID: 60015341